Document:

<PAGE>

                                                                    Exhibit 10.8

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

                              DATE: JANUARY 8, 2007

                           CRITICAL THERAPEUTICS, INC.

                                       AND

                  THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

                           AMENDMENT NO. 2 RELATING TO
                  THE SPONSORED RESEARCH AND LICENSE AGREEMENT
                              DATED JANUARY 1, 2003

--------------------------------------------------------------------------------
                                     Page 1

<PAGE>

                           AMENDMENT NO. 2 RELATING TO
                    SPONSORED RESEARCH AND LICENSE AGREEMENT
                                     BETWEEN
                           CRITICAL THERAPEUTICS, INC.
                                       AND
                  THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
                              DATED JANUARY 1, 2003

THIS AMENDMENT NO. 2 is made the 8th day of January 2007.

BETWEEN:

(1)      CRITICAL THERAPEUTICS, INC., a Delaware corporation ("CTI"); and

(2)      THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, a New York not-for-profit
         corporation ("FEINSTEIN")

RECITALS:

(A)      CTI and Feinstein entered into a Sponsored Research and License
         Agreement dated January 1, 2003.

(B)      The said Sponsored Research and License Agreement was modified by that
         certain Letter Agreement between CTI and Feinstein dated February 3,
         2004, and was amended by that certain Amendment No. 1 dated June 1,
         2006. The Sponsored Research and License Agreement as so modified and
         so amended is referred to herein as the "ORIGINAL AGREEMENT".

(C)      CTI and Feinstein have agreed to amend the Original Agreement by and
         upon the terms of this Amendment No. 2.

OPERATIVE PROVISIONS:

1. INTRODUCTION, DEFINITIONS AND INTERPRETATION

1.1.     This Amendment No. 2 is supplemental to the Original Agreement.

1.2.     In this Amendment, the expression "THIS AMENDMENT NO. 2" shall mean
         this Amendment No. 2, including its recitals and schedules.

1.3.     Except where expressly provided to the contrary in this Amendment No.
         2:

         1.3.1    all capitalized terms used in this Amendment No. 2 shall have
                  the same meanings as are assigned thereto in the Original
                  Agreement, as amended by this Amendment No. 2; and

         1.3.2    this Amendment No. 2 shall be interpreted in the same manner
                  as the Original Agreement.

1.4.     Reference to clauses and Articles herein are to clauses and Articles in
         the Original Agreement.

--------------------------------------------------------------------------------
                                     Page 2
<PAGE>

2. AMENDMENTS

NOW THEREFORE, in consideration of the mutual covenants contained in the
Original Agreement and in this Amendment No. 2 and other good and valuable
consideration the receipt and sufficiency of which is hereby acknowledged, the
parties agree that with effect from the Amendment No. 2 Date (as defined below),
the Original Agreement is hereby amended as follows:

2.1.     Article 1 shall be amended by insertion of the following additional
         definition after Article 1.2.(b).:

         "1.2.(c). AMENDMENT NO. 2 DATE" shall mean January 8, 2007."

2.2.     Article 1.13 shall be deleted in its entirety and the following
         substituted therefor:

         "1.13.   "Research Term" shall mean the five-year period starting on
the Effective Date of this Agreement and any extension of this period mutually
agreed upon by CTI and North Shore."

2.3      Article 2.1 shall be deleted in its entirety and the following
         substituted therefor:

         "2.1     CTI Support. CTI agrees to financially support the Sponsored
Research at Feinstein for the Research Term. The amount of CTI financial support
shall be:

                  First Research Year    Two Hundred Thousand Dollars
                                         ($200,000.00)

                  Second Research Year   Two Hundred Thousand Dollars
                                         ($200,000.00)

                  Third Research Year    Two Hundred Thousand Dollars
                                         ($200,000.00)

                  Fourth Research Year   One Hundred and Fifty Thousand Dollars
                                         ($150,000.00)

                  Fifth Research Year    One Hundred and Twenty Thousand Dollars
                                         ($120,000.00)

Notwithstanding anything to the contrary in this Agreement, Feinstein shall
invoice CTI for (i) 100% of the financial support for the Fourth Research Year
on or after January 8, 2007, (ii) 25% of the financial support for the Fifth
Research Year on or after April 15, 2007, (iii) 25% of the financial support for
the Fifth Research Year on or after July 15, 2007, (iv) 25% of the financial
support for the Fifth Research Year on or after October 15, 2007, and (v) the
balance of the financial support for the Fifth Research Year on or after January
15, 2008." CTI shall make payment by check or wire transfer to Feinstein for
each invoiced amount within one (1) month of the date of CTI's receipt of any
invoice issued by Feinstein pursuant to the immediately preceding sentence.

2.4      ATTACHMENT A shall be deleted in its entirety and the following
         substituted therefor:

--------------------------------------------------------------------------------
                                     Page 3
<PAGE>

                                  "ATTACHMENT A

         RESEARCH PLAN:  CHOLINERGIC ANTI-INFLAMMATORY PATHWAY (CAP) PROGRAM

         1.       [**]

         2.       [**]

         3.       [**]

         4.       [**]

         5.       [**]

         6.       [**]

2.5.     Schedule 1.7 shall be deleted in its entirety and the following
         substituted therefor:

                                  "SCHEDULE 1.7

                           NORTH SHORE PATENT RIGHTS

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------
    NORTH        CTI DOCKET        APPLICATION TITLE        COUNTRY/       APPLICATION     INVENTOR(s)      STATUS
    SHORE            NO.                                   FILE TYPE    NO., FILING DATE
   REF. NO.                                                               AND PRIORITY
----------------------------------------------------------------------------------------------------------------------
<S>              <C>               <C>                     <C>          <C>                <C>              <C>
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
</TABLE>

--------------------------------------------------------------------------------
                                     Page 4

<PAGE>

<TABLE>
<S>              <C>               <C>                     <C>          <C>                <C>              <C>
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
</TABLE>

--------------------------------------------------------------------------------
                                     Page 5

<PAGE>

<TABLE>
<S>              <C>               <C>                     <C>          <C>                <C>              <C>
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
     [**]           [**]                 [**]                 [**]            [**]            [**]            [**]
----------------------------------------------------------------------------------------------------------------------
</TABLE>

* Application is assigned to North Shore-Long Island Jewish Research Institute
and University of Pittsburgh of the Commonwealth System for Higher Education

3. NO OTHER AMENDMENT; CONFIRMATION

Save as amended by this Amendment No. 2, the parties hereto confirm that the
Original Agreement shall continue in full force and effect in all respects.

4. COUNTERPARTS

This Amendment No. 2 may be signed in any number of counterparts with the same
effect as if the signatures to each counterpart were upon a single instrument,
and all such counterparts together shall be deemed an original of this Amendment
No. 2.

5. GOVERNING LAW AND JURISDICTION

This Amendment No. 2 shall be governed by and construed in accordance with the
laws of the State of New York without regard to any conflict of laws provisions
thereof.

IN WITNESS whereof the parties have executed and delivered this Amendment No. 2
as of the date first above written.

CRITICAL THERAPEUTICS, INC.

By: /s/ Trevor Phillips, PhD
    -----------------------------------------------
Name:  Trevor Phillips, PhD
Title: Chief Operating Officer

THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH

By: /s/ Kirk R. Manogue, PhD
    -----------------------------------------------
Name:  Kirk R. Manogue, PhD
Title: Assistant Vice President, Technology Transfer

--------------------------------------------------------------------------------
                                     Page 6<PAGE>

                                                                   Exhibit 10.14

                           CRITICAL THERAPEUTICS, INC.

                                       AND

                               ABBOTT LABORATORIES

                           AMENDMENT NO. 1 RELATING TO
                  THE LICENSE AGREEMENT DATED DECEMBER 18, 2003

<PAGE>

THIS AMENDMENT NO. 1 is made the 13th day of April, 2005

BETWEEN:

(1)      CRITICAL THERAPEUTICS, INC., a corporation organized under the laws of
         the State of Delaware, and with its principal office at 60 Westview
         Drive, Lexington, MA 02421 ("CTI"); and

(2)      ABBOTT LABORATORIES, a corporation organised under the laws of the
         State of Illinois, and having its principal office at 100 Abbott Park
         Road, Abbott Park, Illinois 60064 ("ABBOTT")

RECITALS:

(A)      CTI and Abbott entered into a License Agreement dated December 18, 2003
         ("Original Agreement").

(B)      CTI has moved its principal office from 675 Massachusetts Avenue, 14th
         Floor, Cambridge, Massachusetts 02139 to the principal office stated
         above.

(C)      CTI and Abbott have agreed to amend the Original Agreement by and upon
         the terms of this Amendment No. 1.

OPERATIVE PROVISIONS:

1        INTRODUCTION, DEFINITIONS AND INTERPRETATION

1.1      This Amendment No. 1 is supplemental to the Original Agreement.

1.2      In this amendment, the expression "THIS AMENDMENT NO. 1" shall mean
         this Amendment No. 1, including its recitals and schedules.

1.3      Except where expressly provided to the contrary in this Amendment
         No. 1:

         1.3.1.   all capitalised terms used in this Amendment No. 1 shall have
                  the same meanings as are assigned thereto in the Original
                  Agreement, as amended by this Amendment No. 1; and

         1.3.2.   this Amendment No. 1 shall be interpreted in the same manner
                  as the Original Agreement.

1.4      Reference to articles or sections herein are to articles or sections in
         the Original Agreement.

2        AMENDMENTS

The parties agree that with effect from the Amendment No. 1 Date, the Original
Agreement is hereby amended as follows:

                                       2
<PAGE>

2.1      Article 1 shall be amended by the addition of the following
         definitions:

         ""Amendment No. 1 Date" shall mean April 13, 2005."

2.2      Section 2.1 (ii), second line, shall be amended by the replacement of
         the word "Patents" with the term "Patent Rights".

2.3      Section 2.1 (ii) shall be further amended by the insertion of the words
         "(as such terms are defined in the License Agreement)" between the
         words "Know How" and "pursuant to the License Agreement".

3        NO OTHER AMENDMENT; CONFIRMATION

Save as amended by this Amendment No. 1, the parties hereto confirm that the
Original Agreement shall continue in full force and effect in all respects.

4        COUNTERPARTS

This Amendment No. 1 may be signed in any number of counterparts with the same
effect as if the signatures to each counterpart were upon a single instrument,
and all such counterparts together shall be deemed an original of this Amendment
No. 1.

IN WITNESS whereof the parties have executed and delivered this Amendment No 2
the date first above written.

SIGNED

/s/ Trevor Phillips
--------------------------------------------

for and on behalf of
CRITICAL THERAPEUTICS, INC.

SIGNED

/s/ Suzanne A. Lebold, Ph.D.
--------------------------------------------

for and on behalf of
ABBOTT LABORATORIES

                                       3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]